Dean W Felsher

List of Publications by Citations

158 papers	13,537 citations	56 h-index	115 g-index
172 ext. papers	15,754 ext. citations	10.4 avg, IF	6.39 L-index

#	Paper	IF	Citations
158	Reversible tumorigenesis by MYC in hematopoietic lineages. *Molecular Cell*, **1999**, 4, 199-207	17.6	721
157	MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. *Nature*, **2004**, 431, 1112-7	50.4	689
156	c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. *Genes and Development*, **2006**, 20, 2096-109	12.6	657
155	MYC regulates the antitumor immune response through CD47 and PD-L1. *Science*, **2016**, 352, 227-31	33.3	651
154	MYC as a regulator of ribosome biogenesis and protein synthesis. *Nature Reviews Cancer*, **2010**, 10, 301-9	31.3	570
153	Sustained loss of a neoplastic phenotype by brief inactivation of MYC. *Science*, **2002**, 297, 102-4	33.3	553
152	MYC activation is a hallmark of cancer initiation and maintenance. *Cold Spring Harbor Perspectives in Medicine*, **2014**, 4,	5.4	430
151	Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. *Angewandte Chemie - International Edition*, **2009**, 48, 7668-72	16.4	424
150	HIF-dependent antitumorigenic effect of antioxidants in vivo. *Cancer Cell*, **2007**, 12, 230-8	24.3	410
149	NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. *Nature*, **2016**, 531, 253-7	50.4	367
148	Cancer revoked: oncogenes as therapeutic targets. *Nature Reviews Cancer*, **2003**, 3, 375-80	31.3	342
147	Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 13028-33	11.5	328
146	Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. *Nature Chemistry*, **2014**, 6, 519-26	17.6	314
145	Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. *Journal of Clinical Investigation*, **2015**, 125, 2293-306	15.9	251
144	CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. *Cancer Cell*, **2010**, 18, 485-98	24.3	250
143	c-Myc is a critical target for c/EBPalpha in granulopoiesis. *Molecular and Cellular Biology*, **2001**, 21, 3789-806	4.8	218
142	Cancer prevention and therapy through the modulation of the tumor microenvironment. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S199-S223	12.7	201

141	An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. *Nature Medicine*, **2008**, 14, 979-84	50.5	184
140	Designing a broad-spectrum integrative approach for cancer prevention and treatment. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S276-S304	12.7	179
139	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. *Carcinogenesis*, **2015**, 36 Suppl 1, S254-96	4.6	176
138	Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. *Cancer Cell*, **2014**, 25, 350-65	24.3	158
137	MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. *Cell Metabolism*, **2015**, 22, 1009-19	24.6	152
136	MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 6539-44	11.5	139
135	Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. *Cancer Research*, **2005**, 65, 7159-68	10.1	134
134	MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. *Cancer Cell*, **2014**, 26, 262-72	24.3	132
133	MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. *Cancer Research*, **2011**, 71, 2286-97	10.1	132
132	Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 16266-71	11.5	129
131	Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. *Journal of Hepatology*, **2013**, 59, 1007-13	13.4	127
130	CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. *Science Translational Medicine*, **2013**, 5, 170ra13	17.5	126
129	Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 9974-9	11.5	124
128	Conditional transgenic models define how MYC initiates and maintains tumorigenesis. *Seminars in Cancer Biology*, **2006**, 16, 313-7	12.7	121
127	The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. *Oncogene*, **2018**, 37, 5435-5450	9.2	115
126	Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. *Small*, **2014**, 10, 566-75, 417	11	112
125	Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. *Blood*, **2003**, 101, 2797-803	2.2	110
124	Developmental context determines latency of MYC-induced tumorigenesis. *PLoS Biology*, **2004**, 2, e332	9.7	109

123	Alteration of the lipid profile in lymphomas induced by MYC overexpression. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10450-5	11.5	99
122	Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. *Nature Medicine*, **2009**, 15, 566-71	50.5	91
121	SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. *PLoS ONE*, **2012**, 7, e45119	3.7	87
120	The MYC oncogene is a global regulator of the immune response. *Blood*, **2018**, 131, 2007-2015	2.2	84
119	The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. *Genes and Development*, **2010**, 24, 1281-94	12.6	83
118	Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?. *Cancer Research*, **2008**, 68, 3081-6; discussion 3086	10.1	83
117	Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. *Cancer Research*, **2005**, 65, 4471-4	10.1	83
116	MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. *Cancer Research*, **2006**, 66, 6598-605	10.1	82
115	The effect of environmental chemicals on the tumor microenvironment. *Carcinogenesis*, **2015**, 36 Suppl 1, S160-83	4.6	79
114	MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. *Genes and Cancer*, **2010**, 1, 597-604	2.9	79
113	Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. *Cancer Research*, **2008**, 68, 5132-42	10.1	79
112	Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. *PLoS Genetics*, **2012**, 8, e1002650	6	78
111	Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 4300-4305	11.5	72
110	Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. *PLoS ONE*, **2008**, 3, e2125	3.7	71
109	Hypoxia in models of lung cancer: implications for targeted therapeutics. *Clinical Cancer Research*, **2010**, 16, 4843-52	12.9	69
108	The human BCL6 transgene promotes the development of lymphomas in the mouse. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 14198-203	11.5	68
107	Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. *PLoS Genetics*, **2008**, 4, e1000090	6	67
106	The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse. *American Journal of Pathology*, **2009**, 174, 891-7	5.8	65

105	Reversibility of oncogene-induced cancer. *Current Opinion in Genetics and Development*, **2004**, 14, 37-42	4.9	63
104	Development of a micro-computed tomography-based image-guided conformal radiotherapy system for small animals. *International Journal of Radiation Oncology Biology Physics*, **2010**, 78, 297-305	4	61
103	Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription. *Cell Chemical Biology*, **2019**, 26, 711-723.e14	8.2	60
102	HIF-2α suppresses p53 to enhance the stemness and regenerative potential of human embryonic stem cells. *Stem Cells*, **2012**, 30, 1685-95	5.8	54
101	Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. *Journal of Clinical Investigation*, **2012**, 122, 163-77	15.9	54
100	Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. *Leukemia Research*, **2012**, 36, 98-103	2.7	53
99	The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth. *Cell Metabolism*, **2019**, 30, 556-572.e5	24.6	52
98	Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. *Cancer Research*, **2013**, 73, 1821-30	10.1	52
97	Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. *Seminars in Cancer Biology*, **2004**, 14, 3-11	12.7	50
96	MYC: Master Regulator of Immune Privilege. *Trends in Immunology*, **2017**, 38, 298-305	14.4	49
95	High throughput automated chromatin immunoprecipitation as a platform for drug screening and antibody validation. *Lab on A Chip*, **2012**, 12, 2190-8	7.2	49
94	Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 15400-5	11.5	49
93	BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. *Cancer Research*, **2007**, 67, 11657-67	10.1	49
92	Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. *Blood*, **2007**, 110, 2674-84	2.2	49
91	Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. *Journal of Biological Chemistry*, **2005**, 280, 35713-22	5.4	43
90	MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. *Nature Communications*, **2017**, 8, 15770	17.4	40
89	Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. *Nature Biotechnology*, **2021**, 39, 357-367	44.5	39
88	PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. *Cancer Research*, **2010**, 70, 9022-30	10.1	38

87	Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 4390-5	11.5	38
86	Noninvasive molecular imaging of c-Myc activation in living mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15892-7	11.5	37
85	Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. *PLoS ONE*, **2008**, 3, e2493	3.7	37
84	Conditionally MYC: insights from novel transgenic models. *Cancer Letters*, **2005**, 226, 95-9	9.9	37
83	Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. *Molecular Therapy*, **2010**, 18, 161-70	11.7	35
82	Inactivation of MYC reverses tumorigenesis. *Journal of Internal Medicine*, **2014**, 276, 52-60	10.8	34
81	Survival and death signals can predict tumor response to therapy after oncogene inactivation. *Science Translational Medicine*, **2011**, 3, 103ra99	17.5	34
80	Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 17432-7	11.5	33
79	Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation. *Journal of Immunology*, **2007**, 178, 4315-21	5.3	33
78	"Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. *Oncotarget*, **2012**, 3, 58-66	3.3	33
77	KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. *Leukemia Research* , **2016**, 50, 123-131	2.7	33
76	Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure. *PLoS ONE*, **2009**, 4, e7172	3.7	32
75	Tumor dormancy and oncogene addiction. *Apmis*, **2008**, 116, 629-37	3.4	32
74	Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma **2018**, 6, 125		32
73	Regulates the Stemness Pathway via and to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer Cells. *Cancer Research*, **2019**, 79, 4015-4025	10.1	30
72	Characterization of MYC-induced tumorigenesis by in situ lipid profiling. *Analytical Chemistry*, **2013**, 85, 4259-62	7.8	30
71	A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. *Molecular Cancer Therapeutics*, **2013**, 12, 1896-905	6.1	30
70	Getting at MYC through RAS. *Clinical Cancer Research*, **2005**, 11, 4278-81	12.9	29

69	DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma. *Oncotarget*, **2017**, 8, 76898-76920	3.3	28
68	Role of MYCN in retinoblastoma. *Lancet Oncology, The*, **2013**, 14, 270-1	21.7	27
67	Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. *Advances in Experimental Medicine and Biology*, **2013**, 734, 91-107	3.6	26
66	Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). *Oncotarget*, **2018**, 9, 5517-5528	3.3	26
65	Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. *Cancer Research*, **2010**, 70, 9837-45	10.1	25
64	The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1887-1903	4	25
63	Rehabilitation of cancer through oncogene inactivation. *Trends in Molecular Medicine*, **2005**, 11, 316-21	11.5	24
62	O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. *Journal of Clinical Investigation*, **2018**, 128, 4924-4937	15.9	24
61	Smart Self-Assembly Amphiphilic Cyclopeptide-Dye for Near-Infrared Window-II Imaging. *Advanced Materials*, **2021**, 33, e2006902	24	24
60	SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF. *Bioconjugate Chemistry*, **2009**, 20, 742-9	6.3	23
59	Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models. *Cell Cycle*, **2006**, 5, 1808-11	4.7	23
58	The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. *Nature Reviews Clinical Oncology*, **2021**,	19.4	23
57	Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. *Blood*, **2010**, 115, 4061-70	2.2	22
56	Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. *Clinical and Experimental Immunology*, **2012**, 167, 188-94	6.2	21
55	Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. *Cancer Immunology, Immunotherapy*, **2018**, 67, 47-60	7.4	19
54	Pharmacological inactivation of MYC for the treatment of cancer. *Drug News and Perspectives*, **2003**, 16, 370-4		19
53	Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. *Lymphatic Research and Biology*, **2008**, 6, 149-54	2.3	18
52	A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma. *Hepatology*, **2019**, 70, 1056-1058	11.1	17

51	and cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. *ELife*, **2020**, 9,	8.9	17
50	MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. *Nature Communications*, **2020**, 11, 2860	17.4	16
49	Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. *Cancer Biology and Therapy*, **2007**, 6, 1318-23	4.6	16
48	Activation of Cre recombinase alone can induce complete tumor regression. *PLoS ONE*, **2014**, 9, e107589	3.7	15
47	Oncogene withdrawal engages the immune system to induce sustained cancer regression **2014**, 2, 24		15
46	How Cancers Escape Their Oncogene Habit. *Cell Cycle*, **2003**, 2, 328-331	4.7	15
45	Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. *PLoS ONE*, **2010**, 5, e11367	3.7	15
44	p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. *Oncotarget*, **2015**, 6, 3563-77	3.3	15
43	Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. *Hepatology*, **2021**, 73, 2342-2360	11.2	14
42	Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model. *Oncogene*, **2005**, 24, 6101-7	9.2	13
41	An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. *Immunologic Research*, **2014**, 58, 282-91	4.3	12
40	Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. *Journal of Biological Chemistry*, **2011**, 286, 11035-46	5.4	12
39	(18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. *Cancer Biology and Therapy*, **2008**, 7, 1947-51	4.6	12
38	Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression. *Scientific Reports*, **2019**, 9, 6428	4.9	11
37	Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E3316-24	11.5	11
36	Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. *PLoS ONE*, **2011**, 6, e19758	3.7	11
35	Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. *Hepatology*, **2009**, 49, 471-81	11.2	11
34	A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. *Molecular Cancer*, **2008**, 7, 74	42.1	11

33	Noncanonical roles of the immune system in eliciting oncogene addiction. *Current Opinion in Immunology*, **2013**, 25, 246-58	7.8	10
32	BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia. *Oncotarget*, **2016**, 7, 26926-34	3.3	10
31	Putting oncogenes into a developmental context. *Cancer Biology and Therapy*, **2004**, 3, 942-4	4.6	8
30	MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC. *Molecular Therapy - Nucleic Acids*, **2020**, 21, 850-859	10.7	8
29	Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. *Expert Opinion on Investigational Drugs*, **2013**, 22, 1495-509	5.9	7
28	Conditional Upregulation of IFN-Alone Is Sufficient to Induce Systemic Lupus Erythematosus. *Journal of Immunology*, **2019**, 203, 835-843	5.3	5
27	Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. *Scientific Reports*, **2019**, 9, 16775	4.9	5
26	The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?. *Cancer Research*, **2020**, 80, 3799-3802	10.1	4
25	c-myc, MHCI, and NK resistance in immunodeficiency lymphomas. *Annals of the New York Academy of Sciences*, **1992**, 651, 467-9	6.5	3
24	Intratumoral Administration of the Immunotherapeutic Combination Anti-ctla4, Anti-cd137 and Anti-ox40: Comparison to Systemic Administration, Peri-Draining Lymph Node Injection, and Cellular Vaccine in a Mouse Lymphoma Model. *Blood*, **2016**, 128, 4172-4172	2.2	3
23	ARF: connecting senescence and innate immunity for clearance. *Aging*, **2015**, 7, 613-5	5.6	3
22	Identifying critical signaling molecules for the treatment of cancer. *Recent Results in Cancer Research*, **2007**, 172, 5-24	1.5	2
21	A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation. *Scientific Reports*, **2021**, 11, 1341	4.9	2
20	Affordable Cancer Medications Are Within Reach but We Need a Different Approach. *Journal of Clinical Oncology*, **2016**, 34, 2194-5	2.2	1
19	miR-17-92 explains MYC oncogene addiction. *Molecular and Cellular Oncology*, **2014**, 1, e970092	1.2	1
18	MYC Functions As a Master Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies. *Blood*, **2018**, 132, 2619-2619	2.2	1
17	MYC Functions as a Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies		1
16	Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.. *Nanotheranostics*, **2022**, 6, 243-255	5.6	0

15	Twist1 is required for the development of UVB-induced squamous cell carcinoma. *Molecular Carcinogenesis*, **2021**, 60, 342-353	5	0
14	Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia. *Methods in Molecular Biology*, **2021**, 2318, 297-312	1.4	0
13	In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in relation to tumor growth. *Computational and Mathematical Methods in Medicine*, **2013**, 2013, 802512	2.8	
12	Cooperation between MYC and BCL2 to Induce Lymphoma Is Uncovered in an Adult Context.. *Blood* , **2004**, 104, 1530-1530	2.2	
11	Two Oncogenic Hits Are Required To Initiate Lymphomagenesis in Adult, but Not Neonatal Hosts.. *Blood*, **2005**, 106, 2604-2604	2.2	
10	Nano-Fluidic Detection of Oncoprotein Signaling in Preclinical and Patient Lymphoma Samples.. *Blood*, **2006**, 108, 2527-2527	2.2	
9	ASPP2 Haploinsufficiency Promotes Tumor Formation in a Mouse Model.. *Blood*, **2006**, 108, 4333-4333	2.2	
8	Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons473-510		
7	MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T-Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling. *Blood*, **2019**, 134, 730-730	2.2	
6	Oncogenes and the Initiation and Maintenance of Tumorigenesis **2017**, 143-157		
5	Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na. *Blood*, **2010**, 116, 4010-4010	2.2	
4	Use of nano-immuno assay to generate rapid, quantitative nanoscale proteomic profiling of the hypoxia pathway in renal cell carcinoma clinical specimens.. *Journal of Clinical Oncology*, **2012**, 30, 10513-10513	2.2	
3	Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC.. *Journal of Clinical Oncology*, **2013**, 31, 432-432	2.2	
2	Amphiphilic Cyclopeptide-Dyes: Smart Self-Assembly Amphiphilic Cyclopeptide-Dye for Near-Infrared Window-II Imaging (Adv. Mater. 16/2021). *Advanced Materials*, **2021**, 33, 2170121	24	
1	Azapodophyllotoxin Causes Lymphoma and Kidney Cancer Regression by Disrupting Tubulin and Monoglycerols.. *ACS Medicinal Chemistry Letters*, **2022**, 13, 615-622	4.3	